We have analyzed the folding state of cytosolic proteins imported in vitro into lysosomes, using an approach originally developed by Eilers and Schatz, (Eilers, M., and Schatz, G. (1986) Nature 322, 228 -232) to investigate protein import into mitochondria. The susceptibility toward proteases of mouse dihydrofolate reductase (DHFR), synthesized in a coupled transcriptiontranslation system with rabbit reticulocytes, decreased in the presence of its substrate analogue, methotrexate. This analogue complexes with high affinity with the in vitro synthesized DHFR and locks it into a proteaseresistant folded conformation. DHFR was taken up by freshly isolated rat liver lysosomes and methotrexate reduced this uptake by about 80%. A chimeric DHFR protein, which carries the N-terminal presequence of subunit 9 of ATP synthase preprotein from Neurospora crassa fused to its N terminus, was taken up by lysosomes more efficiently. Again, methotrexate abolished the lysosomal uptake of the fusion protein, which was partially restored by washing of methotrexate from DHFR or by adding together methotrexate and dihydrofolate, the natural substrate of DHFR. Immunoblot analysis with anti-DHFR of liver lysosomes and of other fractions, isolated from rats starved for 88 h and treated with lysosomal inhibitors, suggests that DHFR is degraded by chaperone-mediated autophagy. Competition with ribonuclease A and stimulation by ATP/Mg 2؉ and the heat shock cognate protein of 73 kDa show that the lysosomal uptake of the fusion protein also occurs by this pathway. It is concluded that the lysosomal uptake of cytosolic proteins by chaperone-mediated autophagy mainly occurs by passage of the unfolded proteins through the lysosomal membrane. Therefore, this mechanism is different from protein transport into peroxisomes, but similar to the import of proteins into the endoplasmic reticulum and mitochondria.
1 cisternae into lysosomes, macroautophagy, microautophagy, and a selective pathway for the uptake and degradation of cytosolic proteins mediated by the heat shock cognate protein of 73 kDa (hsc73), also known as chaperone-mediated autophagy.
Endocytosis is the degradative route followed by extracellular proteins, which are either recognized by specific receptors or simply trapped by nonspecific uptake (3) . This is also the degradative pathway followed by plasma membrane proteins which, unlike the low density lipoprotein or the transferrin receptors, do not recycle back to the plasma membrane for reuse. By crinophagy (4), proteins originally destined for secretion are delivered to lysosomes, when the demands for these proteins decline, by a process involving fusion of secretory granules with endosomes and/or lysosomes instead of with the plasma membrane. Also, proteins in transit through the ER, as well as membrane and luminal resident proteins of the ER, can be degraded, under certain conditions, by a direct conversion of cisternae of the transitional part of the ER into lysosomes (5) . In macroautophagy, or classical autophagy, large areas of cytoplasm, typically including whole organelles, are sequestered by a segregating structure and degraded by lysosomes (6, 7) . Microautophagy is a degradative route whereby portions of cytoplasm, including certain organelles such as peroxisomes and/or cellular components down to the level of macromolecules, are directly internalized into the lysosomal matrix by various modifications of the lysosomal membrane which produce intralysosomal vesicles (8) . Finally, in serum-deprived confluent fibroblasts, a selective pathway was described for the degradation of ribonuclease A (RNase A) which required the pentapeptide sequence KFERQ, hsc73, and ATP/Mg 2ϩ (9) . Since its original discovery, the chaperone-mediated autophagic pathway for the uptake and degradation of cytosolic proteins has been found to be also operative in rat liver, especially under long-term starvation (10, 11) , and in kidney and heart, but not in brain, testes, and skeletal muscle (10) . This selective uptake of cytosolic proteins requires KFERQ-like sequences (9) , ATP/Mg 2ϩ , and a cytosolic (12) and an intralysosomal (13, 14) hsc73. In addition, the lysosomal membrane glycoprotein lamp-2a was suggested as a receptor for this pathway (15) . The pathway has been also, at least partially, recon-stituted in vitro with lysosomes from rat liver (16, 17) and from human fibroblasts (12, 18) , as well as with yeast vacuoles (19) . In this latter case, the relationship of the observed uptake with the well established uptake of cytosolic proteins into vesicular intermediates, which is followed by fusion with the vacuolar membrane (20, 21) , remains to be clearly demonstrated. From all this work, it appears that the selective transport of proteins into mammalian lysosomes occurs by a process which resembles, in some respects, the import of proteins synthesized on cytosolic ribosomes into other cell compartments, such as mitochondria, chloroplasts, and the various types of microbodies (peroxisomes, glycosomes, hydrogenosomes, and glyoxysomes) (22) (23) (24) (25) .
Uptake of cytosolic proteins into lysosomes for degradation by the chaperone-mediated autophagic pathway requires the movement of the protein across the lysosomal membrane. Proteins can be transported into organelles either in an unfolded (as, for example, occurs in mitochondria, chloroplasts, or endoplasmic reticulum, see Refs. 22-24 for review) or in a folded conformation (as is the case, for example, for proteins transported into peroxisomes or into the thylakoid membranes of the chloroplast, see Refs. 25 and 26 for review). However, the conformation of the protein as it passes from the cytosol into the lysosomal lumen is still unknown. Since the original work of Eilers and Schatz (27) , the cytosolic enzyme dihydrofolate reductase (DHFR) has been used to investigate the conformation of proteins as they pass across membranes, taking advantage of the fact that its conformation can be stabilized by complexing it with methotrexate. Here, we have analyzed the effect of methotrexate on the uptake by isolated rat liver lysosomes of the cytosolic enzyme DHFR synthesized in vitro in a coupled transcription-translation system with rabbit reticulocytes. From the obtained results we conclude that DHFR passes through the lysosomal membrane mostly in an unfolded conformation.
EXPERIMENTAL PROCEDURES
Materials-Metrizamide (grade I), trypsin, elastase, trypsin inhibitor, elastatinal, phenylmethylsulfonyl fluoride, chymostatin, chloroquine, methotrexate, dihydrofolate, Triton X-100, MOPS, OsO 4 , ATP, creatine phosphate, creatine phosphokinase, ATP-agarose, p-nitrophenol-N-D-acetylglucosaminide, 4-methylumbelliferyl-2-acetamido-2-deoxy-␤-D-glucopyranoside, goat anti-mouse IgM-and goat anti-mouse IgG (HϩL)-alkaline phosphatase conjugates, 5-bromo-4-chloro-3-indolyl phosphate, nitro blue tetrazolium, RNase A, and ribonuclease Sprotein (RNase S-protein) were from Sigma-Aldrich Química S.A. (Madrid, Spain). Leupeptin was from Peptide Institute (Osaka, Japan). Antibodies against hsc73 were obtained from clone 13D3 (mouse immunoglobulin M) from Maine Biotechnology Services (Portland, ME). Anti-DHFR-polyclonal antibodies were raised against 6-His-tagged mouse DHFR cloned in pQE16 (Qiagen, Hilden, Germany) and overexpressed in Escherichia coli. Sodium deoxycholate, uranyl acetate, proteinase K, and sucrose were from Merck (Darmstadt, Germany). Bovine serum albumin (fraction V) was from Roche Molecular Biochemicals (Mannheim, Germany). Acrylamide/Bis 29:1 was from Bio-Rad. Sodium dodecyl sulfate was from Serva (Heidelberg, Germany). Cellulose nitrate paper (0.45 m) was from Schleicher and Schuell (Dassel, Germany). Glutaraldehyde was from Tousimis (Rockville, MD). Epon (Poly/ Bed 812 resin) was from Polysciences (Warrington, PA). TNT-coupled rabbit reticulocyte lysate system was from Promega (Madison, WI 6 histidines on its C terminus, was used for the expression of DHFR. Also, recombinant pGEM3 plasmid (28) containing a SmaI fragment of 777 base pairs, which includes the fusion protein between the presequence and three amino acid residues of the mature part of subunit 9 of the F 0 -ATP synthase of Neurospora crassa and the mouse full-length coding region of DHFR was used. This fusion protein is called hereafter Su9-DHFR for brevity. For in vitro translation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a recombinant pSP64 plasmid, designed pIC328, containing a PstI-BamHI fragment of about 1400 base pairs, which includes the full-length human GAPDH coding region plus additional 5Ј-and 3Ј-non-translated sequences (16) , was used. In vitro transcription and translation of the various DNAs with the TNTcoupled rabbit reticulocyte system was carried out following the manufacturer's instructions.
Proteolytic Susceptibility Measurements-Incubations were carried out at 37°C in a final volume of 20 l. Assays contained 5 l of the standard synthesis reaction, with and without 250 nM methotrexate, 0.1 M triethanolamine buffer, pH 7.6, and elastase (1% in terms of protein and referred to the protein in the rabbit reticulocyte lysate, 111.5 mg of protein/ml). At the times indicated, portions were taken, 50 M elastatinal was added, and the samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and fluorography. Experiments were also carried out with trypsin and trypsin inhibitor with similar results (data not shown).
Preparation of Lysosomes-24-h fasted male Wistar rats (Interfauna Ibérica S.A., San Feliu de Codines, Spain) were used throughout. All rats were fed ad libitum for at least 7 days before the experiments began. In some experiments, rats were treated with leupeptin (2 mg/ 100 g weight, intraperitoneally, 1.5 h before sacrifice). Lysosomes were obtained from a light mitochondrial fraction in a discontinuous metrizamide gradient by a procedure based on that originally developed by Wattiaux et al. (29) . Rats (200 -250 g) were anesthetized with ether and decapitated. 10 g of rat liver were used and homogenate (7 ml of chilled 0.25 M sucrose/g liver) was filtered through cheesecloth and centrifuged in a Sepatech Biofuge 28RS (Heraeus Sepatech GmbH, Osterode, Germany) at 4,800 ϫ g for 10 min and the supernatant at 17,000 ϫ g for 10 min. After resuspension and washing once, the sediment (a light mitochondrial-lysosomal fraction), suspended in 57% metrizamide, was loaded on the bottom of a discontinuous metrizamide gradient (adjusted to pH 7.0). The discontinuous metrizamide gradient consisted of the following layers: 19.8% (top layer, 3.9 ml), 26.3% (3.5 ml), 32.8% (2.2 ml), and 57.0% (2.3 ml).
Centrifugation in the metrizamide gradient was for 90 min in an SW 40 Ti rotor (Beckman) at 141,000 ϫ g. Lysosomes were collected from the most upper layer and the 26.3-19.8% interface, diluted at least five times with 0.3 M sucrose and sedimented at 37,000 ϫ g for 10 min in a Sorvall centrifuge (rotor SS-34). Mitochondria were obtained from the 57-32.8% interface (16) . All procedures were carried out at 0 -4°C. After a quick wash, lysosomes were carefully resuspended in 10 mM MOPS, pH 7.2, and 0.3 M sucrose to a concentration of about 6 mg of lysosomal protein/ml and immediately used for the uptake experiments. Yields were 0.3-0.5 mg of lysosomal protein per g of liver. The appearance of the lysosomes by electron microscopy was not changed during the various incubations used here. The integrity of the lysosomal membranes was also estimated by measuring the latency of the lysosomal enzymes ␤-hexosaminidase and ␤-N-acetylglucosaminidase (11). It was Ͼ94% at the end of the incubations.
In some experiments, two lysosomal fractions were prepared by centrifuging separately the top layer and the 26.3-19.8% interface of the metrizamide gradient as described (14) . These fractions (referred to hereafter as HSCϩ and HSCϪ lysosomes) contained or did not contain, respectively, hsc73 within the lysosomal lumen (Ref. 14 and data not shown).
Cell-free Assay of Transport of Cytosolic Proteins into LysosomesFreshly isolated lysosomes (60 g of protein), treated or not with chymostatin (see below), were incubated, for 10 min at 30°C in a final volume of 40 l, in 0.3 M sucrose, 10 mM MOPS buffer (pH 7.2), containing an ATP-regenerating system (final concentrations: 10 mM MgCl 2 , 10 mM ATP, 2 mM phosphocreatine, and 50 g/ml creatine phosphokinase) (medium S) with the various in vitro synthesized proteins (10 l of the standard synthesis reaction, except where indicated), treated or not with 250 nM methotrexate. Although lysosomes (11, 13, 14) and rabbit reticulocyte lysates (data not shown) do contain hsc73 in enough amounts for lysosomal transport, in most experiments additional hsc73 (5 g/ml, final concentration) was added to the incubation mixture. Chymostatin, when used, was added to the lysosomes at 0°C for 10 min at three times its final concentration (30 M) and then diluted 3-fold with incubation buffer containing the in vitro synthesized proteins. Experiments were also carried out with 10 mM (final concentration) chloroquine with similar results (data not shown). Samples were centrifuged in a Sepatech Biofuge 28 RS (rotor HFA 22.1) at 26,000 ϫ g for 5 min at 4°C, the pellets were quickly washed once and pellets and supernatants were subjected to SDS-PAGE and fluorography. In some experiments, a treatment of proteinase K (20 g/tube) in 0.3 M sucrose/MOPS buffer, pH 7.2, of the washed sediments was carried out, with or without 1% Triton X-100, for 10 min at 0°C. After addition of 2 mM phenylmethylsulfonyl fluoride, samples were centrifuged as above and the pellets and the supernatants were subjected to SDS-PAGE and fluorography.
In experiments with HSCϩ and HSCϪ lysosomes, prior to the standard incubation with the in vitro synthesized proteins and the following treatments, lysosomes were preincubated for 5 min at 30°C with 0.3 M sucrose, 10 mM MOPS buffer, pH 7.2, containing or not hsc73 and/or the ATP-regenerating system. Competition experiments between RNase A and RNase S-protein and the in vitro synthesized proteins, were carried out as described (17) .
Proteolysis Measurements with Freshly Isolated Lysosomes-Chinese hamster ovary cells were grown as described (30) . They were metabolically labeled for 48 h with 25 Ci/dish [ 3 H]leucine and a cytosolic fraction was prepared as described previously (31) . Freshly isolated lysosomes (60 g of protein) were incubated for different times in medium S with the 3 H-labeled cytosolic proteins from Chinese hamster ovary cells (10 g of protein with a specific activity of about 10,000 dpm/g of protein) and 10 l of the reticulocyte lysate transcriptiontranslation mixture, with or without DHFR plus 250 nM methotrexate, in a total volume of 100 l. At 0, 5, 10, 20, 30, and 40 min incubation, aliquots were taken and mixed with 500 l of 10% (w/v) trichloroacetic acid to terminate the reaction. 3 mg of bovine serum albumin were added to each aliquot as carrier protein and the samples were incubated for 10 min on ice and then pelleted by centrifugation. Under these conditions, non-degraded proteins are precipitated, whereas proteolytic fragments remain soluble. To control for the integrity of the isolated lysosomes during the incubation period (16), lysosomes were incubated in parallel as above but without the 3 H-labeled soluble proteins. At 5, 10, 20, 30, and 40 min, lysosomes were removed by centrifugation and supernatants were incubated with 3 H-labeled cytosolic proteins for the same times (5, 10, 20, 30 and 40 min, respectively). The reaction was stopped with trichloroacetic acid plus bovine serum albumin as above. The radioactivity of the acid-soluble and acid-insoluble material (dissolved in 0.2 M NaOH containing 0.4% sodium deoxycholate) was determined by liquid scintillation counting. Degradation was expressed as percentage of the initial acid-insoluble radioactivity remaining at the different incubation times.
General-DNA sequencing was performed using a 377 Automated DNA sequencer of Applied Biosystems (Foster City, CA). Protein concentration was measured by a modification, with sodium deoxycholate (32), of the Lowry et al. (33) method and using bovine serum albumin as the standard. Hsc73 was purified from rat liver cytosol by ATP-agarose affinity chromatography (34) . Cytosol was the supernatant of three successive centrifugations of rat liver homogenates at 2,500 ϫ g, 10 min, 17,000 ϫ g, 10 min and 155,000 ϫ g, 60 min in a Beckman L5-65 centrifuge, Ti-70.1 rotor. SDS-PAGE was done according to Laemmli (35) and gels were used for fluorography. The radioactivity associated with the various proteins in the autoradiograms was quantified by PhosphorImager analysis using a FLA-2000 image analyzer and Science Lab 98 Image Gauge version 3.11 software from FujiFilm Españ a S.A. (Barcelona, Spain). Statistical analyses were carried out with Student's t test. Immunoblotting procedures were carried out as described previously (14, 16) . Lysosomal fractions, treated or not with methotrexate, were fixed and embedded in Epon for conventional electron microscopy by standard procedures (36) . All data shown are representative results of at least three separate experiments.
RESULTS
To test the effect of methotrexate on the conformation of DHFR, aliquots of in vitro synthesized 35 S-labeled DHFR, treated or not with methotrexate (250 nM), were incubated with elastase for increasing time periods (Fig. 1A) . In the absence of methotrexate (lanes [2] [3] [4] [5] , and under the conditions of the experiments, DHFR was degraded, but in its presence (lanes 6 -9), DHFR was protected from elastase by the bound methotrexate.
To follow the import of DHFR into lysosomes, we mixed 35 S-labeled DHFR with freshly isolated rat liver lysosomes in an isotonic medium at pH 7.2 (see "Experimental Procedures") in the absence or presence of chymostatin (to inhibit intralysosomal proteolysis) (Fig. 1B) . This in vitro assay, to monitor the uptake of cytosolic proteins into rat liver lysosomes, has been described in detail (e.g. Refs. 16 and 17). As it is the case with other proteins previously investigated, we also found that, after incubation of the protein with the lysosomes, DHFR was associated with the washed lysosomal pellets (lanes 2 and 5), especially in the presence of chymostatin (lane 2). To eliminate the protein which is simply bound to the external surface of the lysosomal membrane, we used a treatment with an externally added protease (e.g. proteinase K, see "Experimental Procedures"). In the presence of chymostatin, but not in its absence, part of the protein which was untreated with methotrexate was
FIG. 1. Methotrexate protects DHFR from proteolysis by elastase (A) and inhibits its uptake by freshly isolated lysosomes (B and C).
A, effect of methotrexate on the proteolysis by elastase (1%, w/w) of in vitro synthesized DHFR. Lane 1, unincubated DHFR; lanes 2-5, DHFR ϩ elastase incubated at 37°C for 0, 15, 30, and 60 min; lanes 6 -9, DHFR ϩ elastase ϩ methotrexate (250 nM) incubated as in lanes 2-5, respectively. B and C, uptake of in vitro synthesized DHFR by freshly isolated rat liver lysosomes. Aliquots of an in vitro synthesis of DHFR (10 l of total synthesis), non-treated (B, Ϫmethotrexate) or treated (C, ϩmethotrexate) with methotrexate (250 nM), were incubated (lanes 2-7) in the cell-free assay with freshly isolated lysosomes (60 g of protein), with (lanes 2-4) or without (lanes 5-7) 30 M chymostatin, for 10 min at 30°C in medium S (see "Experimental Procedures"). At the end of the incubation, samples were centrifuged and the sediments were resuspended in ice-cold 0.3 M sucrose, 10 mM MOPS buffer, pH 7.2, and treated (lanes 3, 4, 6, and 7) or not (lanes 2 and 5) for 10 min at 0°C with proteinase K, in the presence (lanes 4 and 7) or not (lanes 3 and 6) of Triton X-100, as described under "Experimental Procedures." Then, lysosomes were centrifuged and the pellets were subjected to SDS-PAGE and fluorography. Lane 1 corresponds to 3% of the synthesis, which was incubated with the lysosomes. In the presence of inhibitors of lysosomal proteolysis (lanes 2-4), but not in its absence (lanes 5-7), DHFR untreated with methotrexate (B), is in part inside lysosomes and, therefore, protected against proteinase K (lane 3), unless Triton X-100 (lane 4) is added. The protein associated with lysosomes in the presence of chymostatin (lane 2) roughly corresponds to the sum of lane 3 (internalized DHFR) and lane 5 (protein adsorbed to the external surface of lysosomes). Without chymostatin (lanes 5-7), DHFR associated to lysosomes remains outside, bound to the lysosomal membrane and, thus, sensitive to exogenously added proteinase K (lane 6). According to these same criteria, DHFR treated with methotrexate (C) is not transported and remains outside the lysosomes (compare lanes 3 and 6 in B and C). The positions of molecular mass markers and their size in kDa are indicated on the left.
protected from proteinase K (Fig. 1B, compare lanes 3 and 6) . In the presence of Triton X-100, DHFR associated with lysosomes was degraded by proteinase K (lane 4). These results indicate that, in the absence of methotrexate, DHFR is taken up into lysosomes where it is degraded by lysosomal cathepsins unless chymostatin is present. When the same experiments were carried out in the presence of methotrexate (Fig. 1C) , almost no uptake of DHFR could be detected, independently of the presence of the inhibitor of lysosomal proteases. Thus, under the conditions of the experiment, there was almost no difference in the amount of DHFR associated to the washed lysosomal pellets with or without chymostatin (lanes 2 and 5), and proteinase K released the lysosomal membrane from the associated DHFR (lanes 3 and 6) .
Methotrexate neither affected the activity of elastase (as observed by digestion of albumin by elastase in the presence of 250 nM methotrexate, data not shown), nor the lysosomes which were used in these experiments. Thus, the electron microscopic appearance of lysosomes incubated in the presence of methotrexate for 10 min was not different from that of lysosomes incubated in parallel but without methotrexate (Fig. 2) .
Also, the latency of the lysosomal enzymes ␤-hexosaminidase and ␤-N-acetylglucosaminidase was not modified by the methotrexate treatment (data not shown). Finally, Fig. 3 shows that the association of DHFR and methotrexate neither affects the lysosomal integrity (compare OE with ⌬), nor the proteolytic activity of lysosomes toward an extract of cytosolic proteins (compare f with Ⅺ). Moreover, when a DHFR-unrelated protein (GAPDH) was used in similar assays to those shown in Fig. 1 it was found that methotrexate neither modified the proteolytic susceptibility of GAPDH toward elastase (data not shown) nor the transport of GAPDH into lysosomes (Fig. 4) .
The use of an exogenously added protease (proteinase K) in the assay employed in Fig. 1 , B and C, has some inconveniences when used to quantitatively compare the lysosomal uptake of proteins with very different susceptibilities to proteases, such as DHFR and DHFR-methotrexate. Thus, proteinase K, at the conditions needed to eliminate DHFR-methotrexate from the lysosomal membranes, also affects, to some extent, the lysosomal membrane. This, together with the higher proteolytic susceptibility of DHFR without methotrexate to proteinase K, determines that the amount of DHFR transported into lysosomes, in the absence of methotrexate, might be underestimated. Therefore, to quantify more accurately the effect of methotrexate on the binding and uptake of DHFR, we incubated DHFR expressed in the coupled transcription-translation assay with freshly isolated lysosomes with or without an inhibitor of lysosomal proteases. We have already shown in previous papers (e.g. Refs. 11, 14, 16, 17, and 37) that the protein associated to lysosomes incubated without inhibitors of lysosomal proteases represents the protein bound to the external surface of lysosomes because, under these conditions, the internalized protein is degraded (as confirmed also here by the proteinase K treatment, see Fig. 1B ). In the presence of an inhibitor of lysosomal proteases, part of the protein is insensitive to proteinase K if it is transported into the lysosomes (Fig. 1B, lane 3) . This part represents the protein which has entered into lysosomes and is not degraded by the lysosomal proteases (because they are inhibited) and which is also protected from the exogenously added protease by the lysosomal membrane, unless a detergent (Triton X-100) is added. Therefore, for a specific protein, the protein associated to lysosomes in the presence of inhibitors of lysosomal cathepsins (here chymostatin) represents both the protein bound to the lysosomal membrane (released by proteinase K) and the internalized protein (insensitive to proteinase K). Thus, it is possible to quantify the protein which has been taken up by lysosomes by subtracting the protein associated to lysosomes in the presence (protein bound to the lysosomal membrane and taken up by lysosomes) and absence (protein bound to the lysosomal membrane) of inhibitors of lysosomal proteases (11, 14, 16, 17, 37) . Table I (two upper lines) shows that while the binding of DHFR to the lysosomal membranes, with or without methotrexate, is similar, the uptake of DHFR by lysosomes occurs much more efficiently in the absence of methotrexate.
DHFR is not quite efficiently incorporated into lysosomes (see Table I , two upper lines), in agreement with previous observations from Dice's laboratory (38, 39) . Therefore, we tested a chimeric DHFR protein (Su9-DHFR) with the N-terminal presequence of the precursor polypeptide from N. crassa ATP synthase subunit 9 fused to the N terminus of DHFR (see "Experimental Procedures"). The fusion protein was quite efficiently incorporated into lysosomes (see below), probably because this presequence contains two possible additional KFERQ-like sequences (see "Discussion"). When this construct was incubated with elastase for increasing time periods (Fig. 5A) , we found that, in the absence of methotrexate (lanes 2-5), DHFR was completely degraded. However, in the presence of methotrexate (lanes 6 -9) , the DHFR moiety was protected from the elastase attack by the bound methotrexate.
Here we found, as also observed by others (27) , that the protease cleaves off the unprotected pre-sub 9 extension, because it is in an unfolded state, leaving the DHFR moiety intact, because it is protected by the bound methotrexate. The effect of methotrexate on the binding and uptake by freshly isolated rat liver lysosomes of Su9-DHFR was quantified in four different experiments similar to that shown in Fig. 5B (Table I, two   FIG. 4 . A and B, methotrexate does not affect the transport and uptake of in vitro synthesized GAPDH by freshly isolated rat liver lysosomes. The experiments were carried out as in Fig. 1, B (A) and C (B), except that GAPDH cDNA was used instead of DHFR cDNA. Fig. 5B , lanes 4 and 6, which represents the protein adsorbed to the external surface of the lysosomes) or in the presence (binding ϩ uptake, Fig. 5B, lanes 3 5 . A, effect of methotrexate on the proteolysis of in vitro synthesized Su9-DHFR by elastase (1%, w/w). Lane 1, unincubated Su9-DHFR; lanes 2-5, Su9-DHFR ϩ elastase incubated at 37°C for 15, 30, 45, and 60 min; lanes 6 -9, Su9-DHFR ϩ elastase ϩ methotrexate incubated, respectively, for the same time periods as in lanes 2-5. B, Su9-DHFR is efficiently taken up by lysosomes and methotrexate abolishes this uptake. A cDNA encoding Su9-DHFR was in vitro transcribed and translated in a rabbit reticulocyte system. Lysosomes (60 g), prepared as described under "Experimental Procedures," and treated (ϩ) or not (Ϫ) with an inhibitor of lysosomal cathepsins (chymostatin) were incubated in medium S with Su9-DHFR (10 l of the reticulocyte lysate transcription-translation mixture) for 10 min at 30°C in the presence (ϩ) or absence (Ϫ) of 250 nM methotrexate. After incubation, the lysosomes were pelleted by centrifugation, washed in 0.3 M sucrose, 10 mM MOPS buffer, pH 7.2, and analyzed by SDS-PAGE and fluorography. Lysosomal uptake can be calculated from the difference in the values measured for the Su9-DHFR radioactivity associated to the lysosomal pellets treated (uptake ϩ binding, lanes 3 and 5) or not (binding, lanes 4 and 6) with chymostatin. Lanes 1 and 2 contain, respectively, 6 and 3% of the reticulocyte lysate transcription-translation mixture added to the lysosomes. The positions of molecular mass markers and their size in kDa are indicated on the left. lower lines). These results show again that while the binding of DHFR to the lysosomal membranes, with or without methotrexate, is similar, the uptake of DHFR by lysosomes occurs five times more efficiently in the absence of methotrexate. In both cases, the uptake efficiency of the fusion protein was higher than when DHFR alone was used. These results confirm the importance of an unfolded conformation for the transport of DHFR.
To make sure that Su9-DHFR-methotrexate bound to the lysosomal membrane was on the lysosomal import pathway, we tried to reverse the effect of methotrexate, washing the drug from Su9-DHFR bound to the lysosomal membrane (Fig. 6) . During this procedure, part of the membrane-bound Su9-DHFR was apparently released and there was also some degradation of the imported Su9-DHFR. However, it was clear that partial removal of methotrexate from Su9-DHFR bound to the lysosomal membrane led to an increased import of the fusion protein (Fig. 6A, lanes 4 and 5, compare with lanes 6 and 7, where methotrexate was present, compare also in Fig. 6B , uptake bars in mtx (ϩ/Ϫ) and mtx (ϩ/ϩ)). This import represents about one-third of the total import of the fusion protein subjected to two successive incubations without methotrexate (Fig. 6A, lanes 2 and 3, compare also in Fig. 6B , uptake bars in mtx (ϩ/Ϫ) and mtx (Ϫ/Ϫ)).
Dihydrofolate, the natural substrate of DHFR, binds to DHFR with lower affinity than methotrexate. Thus, we reasoned that DHFR-dihydrofolate could unfold easier than DHFR-methotrexate. As shown in Fig. 7 , dihydrofolate had a much less protective effect than methotrexate on the proteolysis of Su9-DHFR by elastase (lanes 4 and 5 in Fig. 7A and ϩdhf Ϫmtx in Fig. 7B , compare with lanes 6 and 7 in Fig. 7A and Ϫdhf ϩmtx in Fig. 7B ). When methotrexate and dihydrofolate were used together (lanes 8 and 9 in Fig. 7A and ϩdhf ϩmtx in Fig. 7B ), Su9-DHFR was protected to a lower extent than with methotrexate alone, suggesting competition of dihydrofolate and methotrexate for the binding site in DHFR. The same results where obtained with DHFR without the N-terminal presequence of the precursor polypeptide of subunit 9 of ATP synthase (data not shown).
To find out whether there is a correlation between the folding state of DHFR and its lysosomal import, the effect of competition of dihydrofolate with methotrexate on lysosomal import of Su9-DHFR was investigated. Without methotrexate, dihydrofolate alone reduces the uptake of Su9-DHFR by about 50% (Fig. 8A compare lanes 4 -7 and lanes 2 and 3, compare also in Fig. 8B , ϩdhf and Ϫdhf uptake bars). This is probably because dihydrofolate keeps DHFR folded, although less efficiently than methotrexate (see Figs. 7 and 8, C and D) . When dihydrofolate was used together with methotrexate, it was found that the lysosomal uptake of DHFR increased slightly (about 2 times) when compared with methotrexate alone (compare, in Fig. 8C, lanes 4 -7 and lanes 2 and 3, compare also in Fig. 8D , ϩdhf and Ϫdhf uptake bars). These results indicate that dihydrofolate and methotrexate compete for the binding site of DHFR and that dihydrofolate binding keeps DHFR into a more relaxed conformation, as suggested also by the proteolytic susceptibility observations (Fig. 7) . All these observations stress again the importance of an unfolded conformation for an efficient lysosomal transport of a cytosolic protein.
These experiments demonstrate that the folding state of both DHFR and Su9-DHFR affects their uptake by isolated lysosomes. Although this experimental system has been previously shown to reproduce the chaperone-mediated autophagic pathway (11-15, 17, 18, 31, 37, 40) , the following experiments were carried out to show more clearly that both proteins are targeted to lysosomes by this pathway. It is known that in rat liver prolonged starvation (64 -88 h) activates the chaperone-mediated autophagic pathway while reducing the activity of other lysosomal pathways (10, 11) . Therefore, we reasoned that if DHFR follows in vivo the chaperone-mediated autophagic pathway it should be possible to detect, in rats subjected to prolonged starvation, DHFR within liver lysosomes whose proteases are inhibited. Thus, we isolated several liver fractions from rats starved for prolonged periods (88 h) which were injected or not with the lysosomal cathepsins inhibitor leupeptin (Fig. 9A) . As expected, DHFR was detected, by Western blot with an antibody toward DHFR, in whole homogenates (not shown) and in the cytosol of both leupeptin-treated and untreated 88 h-starved rats (Fig. 9B, lanes 1 and 4) . DHFR was not detected in mitochondria and in lysosomes from untreated rats (Fig. 9A, lanes 2 and 3) . However, it was detected in lysosomes (Fig. 9B, lane 6) , but again not in mitochondria (Fig. 9A, lane 5) of leupeptin-treated rats (i.e. it was found in lysosomes with inhibited proteases). Moreover, in leupeptintreated rats, the lysosomal associated protein was partially resistant to a proteinase K treatment which, under the same conditions, completely degrades DHFR in the cytosol (Fig. 9C, compare lines 5 and 2, respectively) . Therefore, it appears that in liver of rats starved for 88 h, a condition under which the chaperone-mediated autophagic pathway is activated, at least part of the DHFR molecules are transported from the cytosol into lysosomes. Similar experiments, carried out with rats starved for 20 h, showed that DHFR was also found within isolated lysosomes from leupeptin-treated rats, but in relatively smaller amounts as compared with lysosomes isolated from the liver of rats starved for 88 h (data not shown). It should be noticed that in livers from rats starved for 20 h, although the chaperone-mediated autophagic pathway is also operative (11), the macroautophagic pathway, which nonselectively degrades all kind of proteins, is strongly activated (1, 6 -8, 11 ).
Su9-DHFR is a chimeric protein which does not exist in vivo and which, in the presence of mitochondria (i.e. under in vivo conditions), would be mainly targeted to these organelles. Although this construct was used here merely as a model to confirm the observations with DHFR, we carried out experiments to investigate if the lysosomal uptake of this protein also occurs by chaperone-mediated autophagy.
In a long series of experiments Dice's laboratory (reviewed in Refs. 9 and 40) showed, both in vivo and in vitro, that RNase A (which contains a KFERQ sequence at amino acids 7-11) follows the chaperone-mediated autophagic pathway of protein degradation. The uptake of RNase A and of other cytosolic proteins by the chaperone-mediated autophagic pathway requires both ATP/Mg 2ϩ and cytosolic and lysosomal hsc73. Although lysosomes (11, 13, 14) and rabbit reticulocyte lysates (data not shown) do contain hsc73 in sufficient amounts for lysosomal transport, we separated, on the basis of their density, two different lysosomal populations (Ref. 14 and data not shown), one containing hsc73 (HSCϩ) and another without this protein (HSCϪ). As shown in Fig. 10 , without additions, the lysosomal uptake of Su9-DHFR is considerably reduced, but HSCϩ lysosomes are slightly more effective than HSCϪ lysosomes in taking up the protein. Preincubation (see "Experimental Procedures") of both lysosomal populations with an ATPregenerating system and hsc73 increased considerably their uptake of Su9-DHFR (Fig. 10A, lanes 2 and 5, compare with lanes 1 and 4, compare also in Fig. 10B , ϩATP ϩhsc73 bars with Control bars). When hsc73 was omitted from the incubation mixture with the ATP-regenerating system, there was a decrease in the uptake of Su9-DHFR by HSCϪ lysosomes (Fig. 10A, lanes 3 and 6, compare with lanes 2 and 5, compare also in Fig. 10B, ϩATP bars with ϩATP ϩhsc73 bars) . This effect was also observed with HSCϩ lysosomes although it was less evident. The same results were obtained when DHFR was used (data not shown). Moreover, and as is the case with RNase A, Su9-DHFR and DHFR are incorporated by lysosomes iso- 2 and 3) or  with (lanes 3-7) the indicated concentrations of dihydrofolate, with freshly isolated lysosomes (60 g of protein), treated  (lanes 2, 4, and 6) or not (lanes 3, 5, and 7) with chymostatin, under standard conditions. Lane 1 corresponds to 12% of the synthesis which was incubated with the lysosomes lated from rats starved for 88 h more efficiently than when using lysosomes from 20-h starved rats (data not shown). All these observations are similar to those obtained in experiments with RNase A (11, 14) .
Finally, and in contrast to RNase A, RNase S-protein (amino acids 21-124 of RNase A and, thus, without a KFERQ sequence) is not a substrate of the chaperone-mediated autophagic pathway (9, 40) . Thus, we carried out competition experiments between RNase A and RNase S-protein with Su9-DHFR for lysosomal uptake. Increasing amounts of RNase A (Fig. 11A ), but not of RNase S-protein (Fig. 11B) , reduced the lysosomal uptake of Su9-DHFR. Similar results were obtained with DHFR (data not shown). All these results taken together show that there are common elements in the lysosomal uptake mechanisms of DHFR and Su9-DHFR and RNase A, which has been extensively shown, both in vivo and in vitro (see see Refs. 9 and 40 for review), to be degraded by chaperone-mediated autophagy. figure (lanes 2-5) . At the end of the incubation, samples were centrifuged, the sediments were treated with proteinase K as described under "Experimental Procedures" and subjected to SDS-PAGE and fluorography. The positions of molecular mass markers and their size in kDa are indicated on the left.
FIG. 9.
Immunolocalization of DHFR in rat liver fractions. Rats starved for 88 h were treated or not with leupeptin and liver fractions were prepared as described under "Experimental Procedures." Proteins (50 g for cytosol and 100 g for mitochondria and lysosomes) were separated by SDS-PAGE and stained with Coomassie Blue R-250 (A) or immunoblotted with anti-DHFR (B and C). A and B, cytosol (CYT, lanes 1 and 4) , mitochondria (MIT, lanes 2 and 5), and lysosomes (LYS, lanes 3 and 6) from rats treated (ϩleupeptin, lanes 4 -6) or not (Ϫleupeptin, lanes 1-3) with leupeptin. C, cytosolic (lanes 1-3) and lysosomal (lanes 4 -6) fractions isolated from rats treated with leupeptin were incubated for 15 min at 0°C without (lanes 1 and 4) or with (lanes 2, 3, 5, and 6) proteinase K (10%, w/w) and in the presence (lanes 3 and 6) or absence (lanes 2 and 5) of 1% Triton X-100. The positions of molecular mass markers and their size in kDa are indicated on the left.
FIG. 10. Effect of ATP/Mg
2؉ and hsc73 on the uptake of Su9-DHFR by two different lysosomal populations. A, Su9-DHFR was incubated, as described under "Experimental Procedures," with freshly isolated HSCϪ (lanes 1-3) and HSCϩ (lanes 4 -6) lysosomes (i.e. not containing or containing lysosomal hsc73, see "Experimental Procedures"), without (lanes 1 and 4) or with an ATP-regenerating system (ATP) plus hsc73 (lanes 2 and 5) or with an ATP-regenerating system alone (lanes 3 and 6) . After incubation, samples were treated with proteinase K as described under "Experimental Procedures," centrifuged, and pellets and supernatants were subjected to SDS-PAGE and fluorography. Only lysosomal pellets are shown; Su9-DHFR in supernatants was totally digested by added proteinase K (data not shown). 
DISCUSSION
In eukaryotic cells, cytoplasmic synthesized proteins can enter into their organelles of residence in either an unfolded conformation (as, for example, in mitochondria) or in a folded conformation (as, for example, in peroxisomes) (22) (23) (24) (25) (26) (41) (42) (43) . The conformation of proteins which enter into lysosomes by chaperone-mediated autophagy is unknown. We decided to approach this problem using DHFR and a procedure first developed by Eilers and Schatz (27) to study the transport of mitochondrial proteins into this organelle.
The mechanism whereby DHFR is degraded in rat liver is unknown. Immunoblot analysis of rat liver fractions revealed the presence of DHFR in the cytosol, as expected, and also within lysosomes from leupeptin-treated rats. Leupeptin enters lysosomes by endocytosis (44) and it has been shown to be very effective in inhibiting, under in vivo conditions, rat liver lysosomal cathepsins (45, 46) . This has allowed the identification of several in vivo substrates of rat liver lysosomes under a variety of conditions. Macroautophagy appears to rapidly respond to starvation (1, 6 -8) and degrades 30 -40% of all rat liver cytosolic proteins during the first 16 -24 h of starvation, but obviously it cannot continue for longer times degrading proteins at such a high rate (11) . Thus, the chaperone-mediated autophagic pathway is primarily activated at later times of starvation, when macroautophagy declines, and selectively degrades dispensable proteins containing KFERQ-like sequences (10, 11) . The fact that there is DHFR associated to lysosomes, whose proteases are inhibited by leupeptin, specially when isolated from rats starved for 88 h (Fig. 9) , suggests that, in rat liver, DHFR is transported from the cytosol into lysosomes by chaperone-mediated autophagy.
Methotrexate binds to DHFR and stabilizes the tertiary structure of the protein so that it cannot unfold efficiently. We were unable to find any indication that methotrexate affected lysosomes or the transport of GAPDH (a DHFR-unrelated protein which does not bind the drug) (Figs. 2-4) . We found, in agreement with others (38, 39) , that DHFR is inefficiently transported in vitro into lysosomes. Therefore, we also used in these experiments a fusion protein of DHFR with the N-terminal presequence of the precursor polypeptide of the subunit 9 of the ATP synthase of N. crassa (Su9-DHFR), which is much more efficiently incorporated (see Table I ). Although this protein does not exist in vivo, it turned out to be a useful model for the investigation of chaperone-mediated autophagy. Figs. 10 and 11 and other experiments (see "Results") show that the rat liver lysosomal uptake of this protein also occurs by chaperonemediated autophagy. The reason why this fusion protein is incorporated into lysosomes with such high efficiency is at present unknown. Mouse DHFR contains 2 KFERQ-related sequences. One is KDRIN (beginning at amino acid 69), if Gln can be replaced by Asn, and the other is RLIEQ (beginning at amino acid 98). The precursor polypeptide of the subunit 9 of the ATP synthase of N. crassa contains two additional motifs (KRTIQ and LKRTQ, starting at amino acids 33 and 45 in the sequence) which could be also considered KFERQ-like sequences if Thr is phosphorylated. Therefore, it is possible that these two additional KFERQ-like motifs have a synergistic effect on the lysosomal uptake of DHFR, either by itself or simply because in the fusion protein the KFERQ-like motifs present in the DHFR molecule are more accessible to the lysosomal transport machinery. Since the presequence is in an unfolded state, another explanation is that partially unfolded proteins are imported with higher efficiencies compared with tightly folded proteins. In any case, it is clear that addition of the precursor polypeptide dramatically increases the lysosomal uptake of DHFR (Table I) .
We found that the transport of DHFR and of the DHFR fusion protein into rat liver lysosomes in vitro was strongly inhibited by addition of methotrexate (Figs. 1, B and C , 5B, and Table I ). We also observed that inhibition of the uptake of DHFR was directly related to the methotrexate-induced folding of DHFR (as assessed by analyses of proteolytic susceptibility) (Figs. 1A and 5A) . Moreover, washing of the drug or addition of dihydrofolate, which competes with methotrexate for DHFR binding and has a lower affinity of binding to DHFR, increased the uptake efficiency of methotrexate-treated DHFR (Figs. 6  and 8, respectively) . These observations may probably be explained if both treatments allow some degree of hsc73-induced unfolding of DHFR. Therefore, DHFR and probably also other cytosolic proteins are transported into the lysosomes through their membranes in an unfolded conformation. According to this model of transport, and assuming that import of the protein starts at its N-terminal portion (17) , when the fusion protein treated with methotrexate interacts with the lysosomal membrane, a membrane-spanning translocation intermediate could accumulate, as the unfolded region crosses the bilayer but the folded moiety gets "stuck." Since, in the absence of chymostatin, the lysosomal proteases are active, they should destroy the unfolded region which has entered the lysosome. Therefore, it may appear surprising that when Su9-DHFR treated with methotrexate is incubated with lysosomes without chymostatin (i.e. which have active the internal cathepsins, Fig. 5B , lane 6) no lower molecular mass band is observed (as it occurs in the incubations with elastase, Fig. 5A , lanes 6 -9, and 7A, lanes 2-9, and with lysosomal cathepsins, data not shown). However, it could be possible that cutting of this part of the molecule releases the fusion protein from its binding to the membrane and, in fact, we found, in the supernatants of these incubations with Su9-DHFR, a lower molecular mass band corresponding to the DHFR size. Another, or an additional, possibility is that the unfolded portion of the protein enters initially into a region of the lysosome which is protected from lysosomal cathepsins. In this regard, it is noteworthy that in most lysosomes of the dense type, it is possible to detect a narrow electron-lucent rim or band of clear lysosomal lumen beneath the limiting lysosomal membrane which separates the inner surface of the lysosomal membrane from the more dense lysosomal core (see Fig. 3, inset) . This area, which has been called a lysosomal "halo" (47, 48) , is believed to correspond to the sugar-rich area of lysosomal proteins on the lysosomal membrane which protects the lysosomal membrane from the attack by their own hydrolases. Since the width of this area is about 30 nm, it may be possible that the unfolded part of the fusion protein (which is 69 amino acids long) was retained in this part of the lysosomes and, in this way, it was not accessible to lysosomal proteases. Thus, assuming a size of 0.5 nm per amino acid, the total length of the N-terminal presequence in its extended conformation will be about 35 nm, which corresponds approximately to the size of the lysosomal halo. If, by analogy with the role in protein transport of other intraorganellar heat shock proteins (22, 49) , intralysosomal hsc73 (11, 13, 14) also acts at the trans side of the lysosomal membrane to provide the driving force to pull the transported protein emerging in the lysosomal lumen, this protective halo may also explain why intralysosomal hsc73, which is susceptible to broken lysosomes, is not immediately degraded within lysosomes by their cathepsins. These possibilities merit further investigation, since a translocation intermediate may be quite useful to identify other components of the putative lysosomal machinery for protein translocation, by procedures similar to those employed with mitochondria (50, 51).
In summary, DHFR and a DHFR fusion protein can be taken up by lysosomes, and methotrexate strongly inhibits the uptake. This suggests, as is the case for the import of proteins into the endoplasmic reticulum and mitochondria, that DHFR enters lysosomes mainly in an unfolded state. This mechanism is different from nonclassical protein-transport pathways (42) , such as in peroxisomes, and may explain our earlier unpublished observations that colloidal gold particles, even when bound to GAPDH, are not efficiently imported in vitro into isolated rat liver lysosomes. Since binding to the lysosomal membrane is not affected by methotrexate, it appears that binding to lysosomes is independent of the folding state of the protein, but that import requires unfolding. In this regard, it has been shown (52), at least in mitochondria, that certain precursor proteins, which assume their native forms before mitochondrial import, are unfolded during translocation. Since hsc73 has been found both in the lysosomal lumen but also associated to the cytosolic face of the lysosomal membrane (11, 13, 14) , it may be possible that this latter hsc73 fraction produces the required unfolding of the proteins which are transported into lysosomes for degradation. In addition, DHFR ϩ methotrexate can be also incorporated into lysosomes, albeit with low efficiencies (about 20% of the import without methotrexate, according to the data in Table I ). Therefore, it appears that either the transport system is not completely strict in requiring an unfolded protein (as may also occur with other cell organelles) or that, as previously suggested (37), two different lysosomal uptake mechanisms coexist in the cell-free assay of lysosomal degradation: a direct transfer through the lysosomal membrane corresponding to chaperone-mediated autophagy and a less effective uptake, under the in vitro conditions used here, which does not require protein unfolding (most probably microautophagy).
